Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study

作者：Caproni Stefano; Corbelli Ilenia; Pini Luigi Alberto; Cupini Maria Letizia; Calabresi Paolo; Sarchielli Paola^*

来源：Cephalalgia, 2011, 31(5): 543-549.

DOI：10.1177/0333102410392605

• Flunarizine
• amytryptiline
• migraine
• orexin
• neuropeptide-Y

Aims: This study was aimed to verify changes in the levels of hypothalamic neuropeptides in migraineurs under preventive treatment with amitryptiline and flunarizine. Thirty-nine migraine patients with a body mass index < 25 kg/m(2) and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months. Orexin-A, orexin-B and neuropeptide-Y plasma levels were measured at the basal time, at the 1st, 2nd and 3rd months of preventive treatment.
Results: A statistically significant reduction in plasma orexin-A and orexin-B levels emerged in both groups. Conversely, plasma neuropeptide-Y levels were markedly increased, with the highest levels at the 2nd and 3rd months, in both patient groups. Orexin-A levels were also negatively correlated to weight gain in both groups during the treatment period.
Conclusions: These results suggest that changes in the levels of hypothalamic orexinergic peptides may contribute to body weight increase occurring in migraineurs during amitryptiline or flunarizine prophylactic treatment.

• 出版日期2011-4